April 1, 2015—The Centers for Medicare & Medicaid Services announced a policy decision about Medicaid drug rebates this week that will result in safety-net healthcare providers getting the same 340B discount percentage on biosimilar medicines as they receive on brand-name drugs.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)